Alchemab Raises £60M ($82M) In Series A Financing To Advance Novel Platform For Identifying Disease-Modifying Antibody Therapeutics
Apr 15, 2021•about 4 years ago
Amount Raised
€60
Round Type
series a
Description
Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round.
FundzWatch™ Score
64
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech